Table 2.

Changes in ICIQ-OAB total and subdomain scores from before the COVID-19 pandemic to 2 mo after COVID infection or at the time of the study

Time point for severity score	Mean score ± standard deviation (range)
	Frequency	Nocturia	Urgency	UUI	Totala
Severity at BL (before the pandemic)	0.4 ± 0.7	1.2 ± 0.5	0.9 ± 0.9	0.7 ± 0.8	3.1 ± 2.1 (1–12)*
Severity at 2 mo after COVID infection (n = 179)b	1.2 ± 1.0	1.8 ± 0.9	1.7 ± 1.0	1.4 ± 1.1	6.2 ± 2.5 (2–15)*
Change in severity score from BL	0.8 ± 0.9 (−1 to 3) *	0.6 ± 0.8 (−1 to 3)*	0.8 ± 0.8 (−1 to 4)*	0.7 ± 0.8 (−1 to 3)*	2.9 ± 2.0 (−1 to 10)*
Change in bother score from BL	2.1 ± 2.7 (−1 to 10)*	2.3 ± 3.3 (−5 to 10)*	2.1 ± 3.2 (−5 to 10)*	2.2 ± 3.5 (−5 to 10)*	N/A
Severity at the time of the study (n = 216)c	1.3 ± 1.1	1.6 ± 0.9	1.6 ± 1.0	1.3 ± 1.0	5.8 ± 2.5 (2 to 15)*
Change in severity score from BL	0.9 ± 0.9 (−1 to 3)*	0.5 ± 0.7 (0 to 3)*	0.7 ± 0.8 (−1 to 4)*	0.6 ± 0.8 (−1 to 3)*	2.7 ± 2.0 (−1 to 11)*
Change in bother score from BL	1.9 ± 2.7 (−5 to 10)*	2.4 ± 3.2 (−2 to 10)*	2 ± 2.9 (−5 to 10)*	2.2 ± 3.5 (−2 to 10)*	N/A

BL = baseline; ICIQ-OAB = International Consultation on Incontinence Questionnaire-overactive bladder; N/A = not applicable; UUI = urge urinary incontinence.

^aThe total score was calculated via a validated methodology as the sum of the symptom severity scores (range 1–16) for all domains without including the bother score.

^bParticipants with a positive polymerase chain reaction test who had 2-mo postinfection data and an increase of ≥1 points for the total ICIQ-OAB score.

^cParticipants with positive COVID status who had an increase of ≥1 points for the total ICIQ-OAB score.

^*Significant at p < 0.0001 on one-way analysis of variance.